<DOC>
	<DOC>NCT00806520</DOC>
	<brief_summary>Obtain Continuous Glucose Monitoring (CGM) data from individuals taking exenatide LAR, sitagliptin, or pioglitazone. The CGM measurements collected will help determine the characteristics of glucose control prior to treatment and during treatment.</brief_summary>
	<brief_title>Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>18 years or older type 2 diabetes A1c 7.1 11 BMI 25 45 stable weight for 3 months before screening fasting glucose &lt; 280 at screening stable dose of metformin for at least 2 months before screening not being treated with or on a stable dose of hormone replacement therapy, oral contraceptives, antihypertensive agents, lipid lowering agents, thyroid replacement therapy, antidepressants, drugs known to affect body weight male or female, nonlactating, nonpregnant and willing to use birth control lab values that are not clinically significant at screening physical exam and ECG that are not clinically significant at screening able to read, understand, and sign consent form liver disease renal disease cardiovascular disease gastroparesis cancer within 5 years of screening macular edema chronic infections drug or alcohol abuse fasting triglycerides &gt; or = 600 at screening previous exposure to exenatide LAR has donated blood within 60 days of screening or is planning to donate during the study has had a major surgery or blood transfusion within 2 months before screening is currently being treated or is expecting to be treated with Byetta, Januvia, SU, TZD, GLP1 analog, alphaglucosidase inhibitor, meglitinide, nateglinide, symlin, insulin, systemic corticosteroids, lopid or rifampin has received an investigational drug within 1 month before screening has allergies or hypersensitivity to any component of the study drug has previously had an adverse event related to TZD or Januvia is an immediate family member of the study sight or directly affiliated is employed by Amylin, Lilly or Alkermes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Continuous Glucose Monitoring</keyword>
	<keyword>Exenatide Once Weekly or</keyword>
	<keyword>Januvia or</keyword>
	<keyword>Actos</keyword>
</DOC>